Neutrophil to Lymphocyte Ratio in Castration-Resistant Prostate Cancer Patients Treated With Daily Oral Corticosteroids
- 10 May 2017
- journal article
- research article
- Published by Elsevier BV in Clinical Genitourinary Cancer
- Vol. 15 (6), 678-684.e1
- https://doi.org/10.1016/j.clgc.2017.05.012
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Abiraterone in Metastatic Prostate Cancer without Previous ChemotherapyNew England Journal of Medicine, 2013
- Circulating myeloid-derived suppressor cells are increased and correlate to immune suppression, inflammation and hypoproteinemia in patients with cancerOncology Reports, 2012
- Interactions of Abiraterone, Eplerenone, and Prednisolone with Wild-type and Mutant Androgen Receptor: A Rationale for Increasing Abiraterone Exposure or Combining with MDV3100Cancer Research, 2012
- Abiraterone and Increased Survival in Metastatic Prostate CancerNew England Journal of Medicine, 2011
- The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insightsMolecular and Cellular Endocrinology, 2010
- Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial dataThe Lancet Oncology, 2009
- Glucocorticoids induce an activated, anti-inflammatory monocyte subset in mice that resembles myeloid-derived suppressor cellsJournal of Leukocyte Biology, 2008
- Glucocorticoids induce differentiation of a specifically activated, anti-inflammatory subtype of human monocytesBlood, 2006
- Antiinflammatory Action of Glucocorticoids — New Mechanisms for Old DrugsNew England Journal of Medicine, 2005
- Regulatory T cells and tolerogenic dendritic cells: from basic biology to clinical applicationsImmunology Letters, 2004